Skip to main content

Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Page 1 of 23

  1. Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) for patients with RAS/BRAF V600E wild-type metastat...

    Authors: Hiromichi Nakajima, Daisuke Kotani, Hideaki Bando, Takeshi Kato, Eiji Oki, Eiji Shinozaki, Yu Sunakawa, Kentaro Yamazaki, Satoshi Yuki, Yoshiaki Nakamura, Takeharu Yamanaka, Takayuki Yoshino, Takashi Ohta, Hiroya Taniguchi and Yoshinori Kagawa

    Citation: BMC Cancer 2021 21:674

    Content type: Study protocol

    Published on:

  2. To evaluate the effectiveness and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during chemoradiotherapy in patients with cervical cancer.

    Authors: Dongling Zou, Mingfang Guo and Qi Zhou

    Citation: BMC Cancer 2021 21:661

    Content type: Research article

    Published on:

  3. In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligibl...

    Authors: Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ganna Usenko, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova…

    Citation: BMC Cancer 2021 21:659

    Content type: Research article

    Published on:

  4. Nutritional complications in patients with locally advanced head and neck cancer (LA-HNC) treated by concurrent chemoradiotherapy (CCRT) often lead to placement of a prophylactic gastrostomy (PG) tube, while i...

    Authors: Tatiana Dragan, Fréderic Duprez, André Van Gossum, Akos Gulyban, Sylvie Beauvois, Antoine Digonnet, Yassine Lalami and Dirk Van Gestel

    Citation: BMC Cancer 2021 21:656

    Content type: Research article

    Published on:

  5. The prognosis of patients with small cell lung cancer (SCLC) is poor, most of them are in the extensive stage at the time of diagnosis, and are prone to brain metastasis. In this study, we established a nomogr...

    Authors: Qinge Shan, Jianxiang Shi, Xiaohui Wang, Jun Guo, Xiao Han, Zhehai Wang and Haiyong Wang

    Citation: BMC Cancer 2021 21:640

    Content type: Research article

    Published on:

  6. Although the National Comprehensive Cancer Network (NCCN) Guidelines recommend CCRT+AC and IC + CCRT as level 2A evidence for treatment of the locoregionally advanced NPC (II-IVa), IC + CCRT+AC could also be a...

    Authors: Wei Liu, Bolong Yu, Yunfan Luo, Junzheng Li, Xiaofei Yuan, Shuting Wu, Bijun Liang, Zehong Lv, Yanfei Li, Xinyu Peng, Juan Lu, Xiaohong Peng and Xiong Liu

    Citation: BMC Cancer 2021 21:639

    Content type: Research article

    Published on:

  7. Radiation-induced pneumonitis (RP) is a non-negligible and sometimes life-threatening complication among patients with thoracic radiation. We initially aimed to ascertain the predictive value of acute radiatio...

    Authors: Wenjie Tang, Xiaolin Li, Haining Yu, Xiaoyang Yin, Bing Zou, Tingting Zhang, Jinlong Chen, Xindong Sun, Naifu Liu, Jinming Yu and Peng Xie

    Citation: BMC Cancer 2021 21:585

    Content type: Research article

    Published on:

  8. Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of se...

    Authors: Young Mi Hong, K. T. Yoon and Mong Cho

    Citation: BMC Cancer 2021 21:569

    Content type: Research article

    Published on:

  9. Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerat...

    Authors: Xinyi Yang, Lay Poh Khoo, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Pooi Ling Tang, Miriam Tao, Soon Thye Lim and Jason Yongsheng Chan

    Citation: BMC Cancer 2021 21:566

    Content type: Research article

    Published on:

  10. The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer ...

    Authors: Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stéphanie Delaine and Marc Ychou

    Citation: BMC Cancer 2021 21:564

    Content type: Study protocol

    Published on:

  11. The platelet-to-lymphocyte ratio (PLR) and C-reactive protein (CRP) level are markers that have been reported to predict the histological type of various tumors, and here, we evaluated their utility in predict...

    Authors: Rui Chen, Liguang Wang, Qi Zhao, Zhen Li, Man Chen, Guodong Lian and Junyong Zhang

    Citation: BMC Cancer 2021 21:556

    Content type: Research article

    Published on:

  12. Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses o...

    Authors: Ting Martin Ma, James M. Lamb, Maria Casado, Xiaoyan Wang, T. Vincent Basehart, Yingli Yang, Daniel Low, Ke Sheng, Nzhde Agazaryan, Nicholas G. Nickols, Minsong Cao, Michael L. Steinberg and Amar U. Kishan

    Citation: BMC Cancer 2021 21:538

    Content type: Study protocol

    Published on:

  13. FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, the evidence is lacking comparing not only two r...

    Authors: Jung Won Chun, Sang Hyub Lee, Joo Seong Kim, Namyoung Park, Gunn Huh, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu and Yong-Tae Kim

    Citation: BMC Cancer 2021 21:537

    Content type: Research article

    Published on:

  14. We reported previously that rectal cancer patients given curative-intent chemotherapy, radiation, and surgery for non-metastatic disease had enhanced risk of metastatic progression and death if circulating lev...

    Authors: Hanna Abrahamsson, Sebastian Meltzer, Vidar Nyløkken Hagen, Christin Johansen, Paula A. Bousquet, Kathrine Røe Redalen and Anne Hansen Ree

    Citation: BMC Cancer 2021 21:535

    Content type: Research article

    Published on:

  15. Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or...

    Authors: Jolanta Żok, Michał Bieńkowski, Barbara Radecka, Jan Korniluk, Krzysztof Adamowicz and Renata Duchnowska

    Citation: BMC Cancer 2021 21:529

    Content type: Research article

    Published on:

  16. The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment pat...

    Authors: Jason Lester, Carles Escriu, Sarah Khan, Emma Hudson, Talal Mansy, Andrew Conn, Samuel Chan, Ceri Powell, Juliet Brock, John Conibear, Lauren Nelless, Vaneet Nayar, Xiaohui Zhuo, Adeline Durand, Amerah Amin, Peter Martin…

    Citation: BMC Cancer 2021 21:515

    Content type: Research article

    Published on:

  17. While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to res...

    Authors: Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Veerle Surmont, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, Dirk Van Gestel, Vincent Renard, Piet Dirix, Pieter Mestdagh…

    Citation: BMC Cancer 2021 21:514

    Content type: Study protocol

    Published on:

  18. Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth f...

    Authors: Lucheng ZHU, Changlin Zou, Zhanchun Zhang, Jianfang Wang, Li Yang, Chuangzhou Rao, Zhiping Yang, Jiafeng Liang, Bing Xia and M. A. Shenglin

    Citation: BMC Cancer 2021 21:511

    Content type: Study protocol

    Published on:

  19. Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to anemia. Multiple RBC transfusions cause secondary iron overload and subsequent excessive generation of react...

    Authors: Lap Shu Alan Chan, Lilly ChunHong Gu and Richard A. Wells

    Citation: BMC Cancer 2021 21:509

    Content type: Research article

    Published on:

  20. Chimeric antigen-receptor T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of autologous stem-cell transplantation (ASCT) in lymphoma. Patients who are likely to p...

    Authors: Kristina Noring, Mattias Carlsten, Kristina Sonnevi and Björn Engelbrekt Wahlin

    Citation: BMC Cancer 2021 21:500

    Content type: Research article

    Published on:

  21. A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefore, the goal of this retrospective study was to in...

    Authors: Matthias Kelm, Julia Schollbach, Friedrich Anger, Armin Wiegering, Ingo Klein, Christoph-Thomas Germer, Nicolas Schlegel, Volker Kunzmann and Stefan Löb

    Citation: BMC Cancer 2021 21:490

    Content type: Research article

    Published on:

  22. This retrospective study aimed to evaluate the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) and to elucidate potential m...

    Authors: Xia Wang, Zhimin Zeng, Jing Cai, Peng Xu, Pingan Liang, Yuxi Luo and Anwen Liu

    Citation: BMC Cancer 2021 21:482

    Content type: Research article

    Published on:

  23. The initial therapeutic strategy for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is based on the first metastatic site; however, little evidence is available regarding the influence of...

    Authors: Jun Yamamura, Shunji Kamigaki, Junya Fujita, Hiroki Osato, Hironobu Manabe, Yumiko Tanaka, Wataru Shinzaki, Yukihiko Hashimoto and Yoshifumi Komoike

    Citation: BMC Cancer 2021 21:476

    Content type: Research article

    Published on:

  24. The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cance...

    Authors: Safa Najafi, Maryam Ansari, Vahid Kaveh and Shahpar Haghighat

    Citation: BMC Cancer 2021 21:454

    Content type: Research article

    Published on:

  25. Radiotherapy, along with laser surgery, is considered a standard treatment option for patients with early glottic squamous cell cancer (SCC). Historically, patients have received complete larynx radiotherapy (...

    Authors: Houda Bahig, David I. Rosenthal, Félix-Phuc Nguyen-Tan, David C. Fuller, Ying Yuan, Katherine A. Hutcheson, Apostolos Christopoulos, Anthony C. Nichols, Kevin Fung, Olivier Ballivy, Edith Filion, Sweet Ping Ng, Louise Lambert, Jennifer Dorth, Kenneth S. Hu and David Palma

    Citation: BMC Cancer 2021 21:446

    Content type: Study protocol

    Published on:

  26. To explore the feasibility of adjuvant surgery following concurrent chemoradiation therapy (CCRT) in stage IIB–IIIB (according to FIGO staging of 2009) cervical cancer and analyze risk factors of recurrence af...

    Authors: Yong Li, Zhiying Chen, Xiang Wang, Xiumei Li, Jie Zhou and Yongchun Zhang

    Citation: BMC Cancer 2021 21:442

    Content type: Research article

    Published on:

  27. Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyon...

    Authors: Francesco Spagnolo, Andrea Boutros, Federica Cecchi, Elena Croce, Enrica Teresa Tanda and Paola Queirolo

    Citation: BMC Cancer 2021 21:425

    Content type: Research article

    Published on:

  28. Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the ...

    Authors: Saber Amin, Michael Baine, Jane Meza and Chi Lin

    Citation: BMC Cancer 2021 21:387

    Content type: Research article

    Published on:

  29. Gliomas are often associated with symptoms including seizures. Most patients with high-grade gliomas are treated with radiotherapy or radio-chemotherapy. Since irradiation causes inflammation, it may initially...

    Authors: Dirk Rades, Jaspar Witteler, Denise Olbrich, Peter Trillenberg, Steven E. Schild, Soeren Tvilsted and Troels W. Kjaer

    Citation: BMC Cancer 2021 21:386

    Content type: Study protocol

    Published on:

  30. Herein, we investigate the relationship between pancreatic stem cell markers (PCSC markers), CD44, and epithelial-specific antigen (ESA), tumor stroma, and the impact on recurrence outcomes in pancreatic ducta...

    Authors: Gokce Askan, Ibrahim Halil. Sahin, Joanne F. Chou, Aslihan Yavas, Marinela Capanu, Christine A. Iacobuzio-Donahue, Olca Basturk and Eileen M. O’Reilly

    Citation: BMC Cancer 2021 21:385

    Content type: Research article

    Published on:

  31. The dose perturbation effect of immobilization devices is often overlooked in intensity-modulated radiation therapy (IMRT) for breast cancer (BC). This retrospective study assessed the dosimetric effects of su...

    Authors: Ran Lv, Guangyi Yang, Yongzhi Huang and Yanhong Wang

    Citation: BMC Cancer 2021 21:384

    Content type: Research article

    Published on:

  32. Epiplakin1 (Eppk1) is part of epidermal growth factor (EGF) signal and takes part in reorganization of cytoskeleton and cell proliferation. However, the role of Eppk1 in cervical cancer (CC) remains unknown.

    Authors: Dong Ma, Zhe Pan, Quan Chang, Jin-jin Zhang, Xiao Liu, Na Hua and Guo-Hua Li

    Citation: BMC Cancer 2021 21:377

    Content type: Research article

    Published on:

  33. The abundance of immune and stromal cells in the tumor microenvironment (TME) is informative of levels of inflammation, angiogenesis, and desmoplasia. Radiomics, an approach of extracting quantitative features...

    Authors: Dooman Arefan, Ryan M. Hausler, Jules H. Sumkin, Min Sun and Shandong Wu

    Citation: BMC Cancer 2021 21:370

    Content type: Research article

    Published on:

  34. A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgk...

    Authors: Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake and Yasuhito Terui

    Citation: BMC Cancer 2021 21:358

    Content type: Research article

    Published on:

  35. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of Hodgkin lymphoma. There is limited data on treatment, management of refractory and relapsed disease, and long-term outcome. Man...

    Authors: Saad Akhtar, M. Shahzad Rauf, Yasser Khafaga, Amani Al-Kofide, Tusneem Ahmed M. Elhassan, Mahmoud A. Elshenawy, Juzer Nadri, Ali Hassan Mushtaq, Nasir Bakshi, Mohammed Shamayel, Suleiman Al-Sweedan, Sohail Sarwar and Irfan Maghfoor

    Citation: BMC Cancer 2021 21:351

    Content type: Research article

    Published on:

  36. Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated th...

    Authors: Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano, Ryota Kominami, Keisuke Tomii, Hidekazu Suzuki, Tomonori Hirashima, Satoshi Tanaka, Junji Uchida…

    Citation: BMC Cancer 2021 21:346

    Content type: Research article

    Published on:

  37. Small-cell lung cancer (SCLC) is a highly proliferative, rapidly growing tumor with a poor prognosis, even in cases of limited disease (LD). Timely and accurate high-intensity therapy is necessary. For concurr...

    Authors: Seo Ree Kim, Ji Hyung Hong, Soo-Yoon Sung, Yeo Hyung Kim, Sang Hoon Chun, Hyun Woo Lee, Jung Soo Lee and Yoon Ho Ko

    Citation: BMC Cancer 2021 21:340

    Content type: Research article

    Published on:

  38. Complete surgical remission (CSR) is the best predictor of overall survival (OS) for patients with metastatic osteosarcoma. However, metastasectomy has not been widely implemented in China in the last decade d...

    Authors: Lu Xie, Jie Xu, Xiaowei Li, Zuli Zhou, Hongqing Zhuang, Xin Sun, Kuisheng Liu, Xingyu Liu, Kunkun Sun, Yiming Wu, Jin Gu and Wei Guo

    Citation: BMC Cancer 2021 21:337

    Content type: Research article

    Published on:

  39. Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage...

    Authors: Mathilde Colombié, Pascal Jézéquel, Mathieu Rubeaux, Jean-Sébastien Frenel, Frédéric Bigot, Valérie Seegers and Mario Campone

    Citation: BMC Cancer 2021 21:333

    Content type: Study protocol

    Published on:

  40. Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resist...

    Authors: Chih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, Chin-Chou Wang, John Wen-Cheng Chang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo and Cheng-Ta Yang

    Citation: BMC Cancer 2021 21:309

    Content type: Research article

    Published on:

  41. The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast cancer. Recently, studies showed that cyclin-dependent kinase (CDK) 4/6 inhibitor, when adde...

    Authors: Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G. Hanna, Shankar Siva, Shom Goel and Steven David

    Citation: BMC Cancer 2021 21:303

    Content type: Study protocol

    Published on:

  42. While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are rel...

    Authors: Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto and Ryuhei Okuyama

    Citation: BMC Cancer 2021 21:287

    Content type: Research article

    Published on:

  43. To investigate the beam complexity and monitor unit (MU) efficiency issues for two different volumetric modulated arc therapy (VMAT) delivery technologies for patients with left-sided breast cancer (BC) and na...

    Authors: Chengqiang Li, Cheng Tao, Tong Bai, Zhenjiang Li, Ying Tong, Jian Zhu, Yong Yin and Jie Lu

    Citation: BMC Cancer 2021 21:261

    Content type: Research article

    Published on:

  44. Alpha-fetoprotein-negative hepatocellular carcinoma (AFP-NHCC) (< 8.78 ng/mL) have special clinicopathologic characteristics and prognosis. The aim of this study was to apply a new method to establish and vali...

    Authors: Dongdong Zhou, Xiaoli Liu, Xinhui Wang, Fengna Yan, Peng Wang, Huiwen Yan, Yuyong Jiang and Zhiyun Yang

    Citation: BMC Cancer 2021 21:246

    Content type: Research article

    Published on:

  45. AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed...

    Authors: Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara…

    Citation: BMC Cancer 2021 21:230

    Content type: Research article

    Published on:

  46. Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is an important cancer stem cell marker in gastric cancer. However, no detailed studies are available on LGR5 expression in poorly differentiated...

    Authors: Takehito Ehara, Takeshi Uehara, Tomoyuki Nakajima, Yasuhiro Kinugawa, Shota Kobayashi, Mai Iwaya, Hiroyoshi Ota and Yuji Soejima

    Citation: BMC Cancer 2021 21:228

    Content type: Research article

    Published on:

  47. Due to recent concerns about the toxicity of trastuzumab emtansine (T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-D...

    Authors: Matthew N. Mills, Chelsea Walker, Chetna Thawani, Afrin Naz, Nicholas B. Figura, Sergiy Kushchayev, Arnold Etame, Hsiang-Hsuan Michael Yu, Timothy J. Robinson, James Liu, Michael A. Vogelbaum, Peter A. Forsyth, Brian J. Czerniecki, Hatem H. Soliman, Hyo S. Han and Kamran A. Ahmed

    Citation: BMC Cancer 2021 21:223

    Content type: Research article

    Published on: